Find therapies in clinical trials near you – page 325

Study on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis

Study on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis

Study on Filgotinib for Children and Teens with Juvenile Idiopathic Arthritis

Study on Filgotinib for Children and Teens with Juvenile Idiopathic Arthritis

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Study on Lorlatinib for Patients with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer Continuing from Previous Studies

Study on Lorlatinib for Patients with ALK-Positive or ROS1-Positive Non-Small Cell Lung Cancer Continuing from Previous Studies

Study on SENS-501 for Children with Severe Hearing Loss Due to Otoferlin Gene Mutations

Study on SENS-501 for Children with Severe Hearing Loss Due to Otoferlin Gene Mutations

Study on the Effectiveness and Safety of Epcoritamab Alone or with Lenalidomide for Patients with Diffuse Large B-Cell Lymphoma Who Cannot Use Anthracyclines

Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

Study of BMS-986158 Alone and with Ruxolitinib or Fedratinib for Patients with Intermediate or High Risk Myelofibrosis

Study on Immunosuppressive Therapies with Asfotase Alfa for Patients with Hypophosphatasia Experiencing Reduced Treatment Effectiveness

Study on Immunosuppressive Therapies with Asfotase Alfa for Patients with Hypophosphatasia Experiencing Reduced Treatment Effectiveness